Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas
Helena Leijon, Satu Maria Remes, Jaana Hagström et al. · Human Pathology · 2018
Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are neuroendocrine tumors that express somatostatin receptors (SSTRs), a phenomenon that constitutes a basis for tumor imaging and treatment with somatostatin analogues and peptide receptor radionuclide therapy. We studied the immunohistochemical expression of SSTR1-5 in 151 primary tumors, including 14 metastasized and 16 SDHB-deficient tumors. SSTR2 and SSTR3 were most abundantly present in these tumors, whereas the tumors were mostly negative for SSTR1, SSTR4, and SSTR5. All metastasized PGLs (9/9), but only one metastasized PHEO (1/5), were strongly SSTR2 positive. SSTR3 expression was lower in metastatic tumors and tumors with a high proliferation rate (MIB1 ≥ 5%), but tumors had variable individual SSTR profiles. No correlation was found between SDHB status and SSTR expression. Our results suggest that new SSTR analogues with affinity for several SSTRs could be relevant for a subgroup of patients with these tumors. Better knowledge of tumor SSTR profiles could open the door for personalized imaging and treatment in the future. Because SSTR profiles vary in PHEOs and PGLs, individual analysis is required for each tumor. • Pheochromocytomas and paragangliomas have individual somatostatin receptor profiles. • Metastatic paragangliomas are somatostatin receptor 2 positive by IHC. • Metastatic pheochromocytomas are mostly somatostatin receptor 2 negative by IHC. • Metastatic tumors express less somatostatin receptor 3 than nonmetastatic tumors.
Cited by 61 works. doi:10.1016/j.humpath.2018.11.020 Open-access PDF
Authors
- Helena Leijon
- Satu Maria Remes
- Jaana Hagström
- Johanna M. Louhimo
- Hanna O Mäenpää
- Camilla Schalin‐Jäntti
- Markku Miettinen
- Caj H. Haglund
- Johanna Arola
References
- WHO Classification of Tumours of Endocrine Organs
- Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
- DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals
- Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy
- Pheochromocytoma and Extra-adrenal Paraganglioma: Updates
- Somatostatin Receptor Subtypes in Human Pheochromocytoma: Subcellular Expression Pattern and Functional Relevance for Octreotide Scintigraphy
- 15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1–5
- SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T)
- Radiopeptide Imaging and Therapy in Europe
- Phaeochromocytoma and paraganglioma